Clinical trial · Interventional
Effectivenes of Cyanoacrylate (Glubran 2®) in Reducing Seroma Formation in Breast Cancer Patients Post-Axillary Dissection
NCT02141373CI-TRIAL-00017386unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Glubran 2 as a surgical glue maybe effective in reducing seroma formation post axillary dissection in breast cancer patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Glubran 2 | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Glubran 2
- description
- Glubran 2 will be used at end of surgery
- interventionNames
- Device: Glubran 2
- type
- NO_INTERVENTION
- label
- Standard Surgery
Primary outcomes (2)
- measure
- Total drainage volume
- timeFrame
- 3 months
- measure
- Total seroma aspirate volume
- timeFrame
- 3 months
Secondary outcomes (5)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * The Patient should be above 18 years old * The Patients has Node positive breast cancer * The Patient is eligible for axillary dissection in addition to a surgical intervention for the primary tumor * Patients whose sentinel lymph nodes test positive during surgery. * The patient is willing to sign an informed consent to participation Exclusion Criteria: * Platelet count is less than 100000 * Obese patients with a BMI of more than 35 * Patients who need immediate breast reconstruction surgery * Patients who are receiving anticoagulation therapy or have coagulation disorders * Pregnant or lactating patients * Patients who are on steroid therapy * Patients who received chest radiotherapy * Patients who received neoadjuvant chemotherapy
References
Publications (1)
- DERIVEDAl-Masri M, Alawneh F, Daoud F, Ebous A, Hamdan B, Al-Najjar H, Al-Masri R, Abufara M. Effectiveness of Cyanoacrylate in Reducing Seroma Formation in Breast Cancer Patients Post-Axillary Dissection: A Randomized Controlled Trial. Front Oncol. 2021 Jan 25;10:580861. doi: 10.3389/fonc.2020.580861. eCollection 2020. PMID 33569343